Purchase Order 75N95020P00674

The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $63,800.00 firm fixed price purchase order contract to Pelago Bioscience AB, a for-profit limited liability company, to perform "Small Molecule Target Deconvolution via Cellular Thermal Shift Assay (CETSA)." This requirement was originally posted as a Sources Sought notice, seeking information on qualified sources to perform CETSA experiments, including sample...

<p>The U.S. Federal Agency, Office of Logistics and Acquisition Operations, awarded a Firm Fixed Price Purchase Order contract to 3Xper Innoventure LTD, a foreign-owned for-profit manufacturing organization, to MANUFACTURE THE SMALL MOLECULES TO INCREASE THE TRANSLATIONAL POTENTIAL. The contract has a ceiling value of $24,200.00 and a performance period ending on December 8, 2025. The contract was awarded on December 9, 2024 and does not have a set-aside designation.</p>

The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $3.86 million firm fixed price purchase order to Molecular Devices LLC for the acquisition of five Molecular Devices ImageXpress Confocal High-Content Imaging Systems, one FLIPR Penta high-throughput cellular screening system, along with associated software, services, consumables, installation, training, customization, maintenance, and technical support. The products and services are to support the...

This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Signablok, Inc., a biopharmaceutical company, for a Small Business Innovation Research (SBIR) Phase I project. The contract is for research and development of a first-in-class TREM-1 radioprotector to prevent the effects of acute radiation syndrome. The project has a total potential value of $220,006.07 and is a set-aside designated for small businesses. Signablok has received previous SBIR grant funding from...

This is a federal contract award from the U.S. Department of Health and Human Services (HHS) to Molecular Insight Pharmaceuticals, Inc., a small business, for the development of peptides for imaging and therapy using Screening Arrays for Addressable Configurations (SAAC) and High Throughput Screening (HTS) under the Small Business Innovation Research (SBIR) program. The firm-fixed-price contract, valued at $492,324.00, was awarded on September 30, 2006 with a completion date of December 31,...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...

This is a $20,960 fixed-price purchase order contract awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency, to the JAI Research Foundation, a non-profit organization. The contract is for solubility, stability, and toxicology studies to advance novel drug candidates developed by the NIDDK into clinical trials. This contract was awarded on September 25, 2020 and has a completion date of September 24, 2021. The contract stems from a small...

This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences, a civilian federal agency, to Editco Bio Inc., a self-certified small disadvantaged business. The contract, valued at $24,150.00, is for the delivery of 2 SFRP1-HIBIT-TAGGED CELL LINES FOR SMALL MOLECULE SCREENING. The contract has an ultimate completion date of April 30, 2025 and was awarded on December 11, 2024. This contract is not associated with a larger vehicle and does...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $110,000.00 firm fixed price purchase order to Reaction Biology Corporation, a self-certified small disadvantaged business, for the testing of compounds to inhibit wild-type kinase enzymes. This requirement does not have a set-aside designation. Reaction Biology Corporation is a contract research organization that provides specialized bioassay testing and...

This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The $102,100 contract is for testing 10 novel small molecule compounds against a panel of 50 wild-type kinases, as well as testing 5 compounds against a more comprehensive panel of 374 wild-type kinases. The purpose is to assess the kinase...